[Comparative study of low molecular dextran or hydroxyethyl starch as a volume substitute in hemodilution therapy]
- PMID: 2419635
- DOI: 10.1007/BF01721578
[Comparative study of low molecular dextran or hydroxyethyl starch as a volume substitute in hemodilution therapy]
Abstract
Rheological therapy, as an immediate treatment in conjunction with physical therapy and the removal of risk factors, plays a significant role in the management of patients with peripheral vascular disease experiencing reduced walking tolerance. An essential element of rheological therapy is hemodilution. Currently, is still uncertain which plasma substitute solution would be the most appropriate in such cases. This study compared the effectiveness of low molecular hydroxyethyl starch to low molecular dextran during a 16-day hemodilution in combination to physical therapy. The clinical improvement observed with both plasma substitute solutions was comparable, yet in view of the cardiac volume overload, dextran demonstrates greater circulatory stress due to the transient pressure increase and more side effects. For this reason, we prefer to administer low or middle molecular hydroxyethyl starch in the dilution treatment of peripheral arterial occlusive disease as a chronic degenerative vascular disease.
Similar articles
-
[Hemodilution in patients with stage IIb peripheral arterial occlusive disease: prospective randomized double-blind comparison of middle-molecular weight hydroxyethyl starch and low-molecular weight dextran solution].Klin Wochenschr. 1987 Apr 1;65(7):324-30. doi: 10.1007/BF01745387. Klin Wochenschr. 1987. PMID: 2438451 Clinical Trial. German.
-
[Effect of a 10% and 6% hydroxyethyl starch solution (molecular weight 200,000/0.62) in comparison with a 10% dextran solution (molecular weight 40,000) on flow properties of blood and tissue oxygen pressure in patients with intermittent claudication].Infusionstherapie. 1988 Oct;15(5):181-7. Infusionstherapie. 1988. PMID: 2461906 Clinical Trial. German.
-
Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb.J Intern Med. 1990 Feb;227(2):107-14. doi: 10.1111/j.1365-2796.1990.tb00127.x. J Intern Med. 1990. PMID: 1688914 Clinical Trial.
-
[Hemodilution in the treatment of cerebrovascular disorders].Neurol Neurochir Pol. 1991 Mar-Apr;25(2):247-54. Neurol Neurochir Pol. 1991. PMID: 1717868 Review. Polish.
-
Rational use of albumin and plasma substitutes.Johns Hopkins Med J. 1975 May;136(5):220-5. Johns Hopkins Med J. 1975. PMID: 47936 Review.
Cited by
-
[Hemodilution in patients with stage IIb peripheral arterial occlusive disease: prospective randomized double-blind comparison of middle-molecular weight hydroxyethyl starch and low-molecular weight dextran solution].Klin Wochenschr. 1987 Apr 1;65(7):324-30. doi: 10.1007/BF01745387. Klin Wochenschr. 1987. PMID: 2438451 Clinical Trial. German.
-
Haemodilution with dextran 40 and hydroxyethyl starch and its effect on cerebral microcirculation.J Neurol. 1989 Mar;236(3):164-7. doi: 10.1007/BF00314334. J Neurol. 1989. PMID: 2468744